AHZ management and it's technologies are both first rate yet I have seen many companies with a first rate technology fail to flourish due to poor strategy execution by management. Managements stated strategy with CardioCel is to get it into the hands of the world's best surgeons and the most respected CHD centres around the world and so far they are succeeding admirably with 12 major centres in The EU and 9 in The US. I do not know for certain that these are 'major' centres although this was the stated aim by management in their presentations…..
If AHZ can get the best surgeons at the leading centres using CardioCel and establish the technologies superior competitive advantages through 'professional proof' then surgeons from the lesser tier establishments will almost certainly start using it also and a snowball effect with sales will ensue.
For this reason I found the invitation to '1st European CardioCel Expert Meeting' in Berlin very interesting. Let's hope there are many more to follow and not just in Europe but around the whole world.
http://www.admedus.com/us/wp-content/uploads/sites/2/2013/07/1st-Expert-Meeting-letter-FINAL.pdf
http://www.admedus.com/us/wp-content/uploads/sites/2/2013/07/EU_Expert-Meeting_26-9-.pdf
AHZ management and it's technologies are both first rate yet I...
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |